INT291018

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.98
Pain Relevance 0.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (NSF) vesicle-mediated transport (USE1) endoplasmic reticulum (USE1)
plasma membrane (NSF) lysosome (USE1) cytoplasm (NSF)
Anatomy Link Frequency
liver 1
kidney 1
NSF (Homo sapiens)
USE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 54 100.00 Very High Very High Very High
imagery 12 50.00 Quite Low
tolerance 2 5.00 Very Low Very Low Very Low
Multiple sclerosis 2 5.00 Very Low Very Low Very Low
cINOD 2 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Nephrogenic Fibrosing Dermopathy 56 100.00 Very High Very High Very High
Renal Insufficiency 24 69.20 Quite High
Nephrotoxicity 10 5.00 Very Low Very Low Very Low
Increased Venous Pressure Under Development 6 5.00 Very Low Very Low Very Low
Renal Disease 4 5.00 Very Low Very Low Very Low
Hypersensitivity 4 5.00 Very Low Very Low Very Low
Thrombosis 2 5.00 Very Low Very Low Very Low
Fibrosis 2 5.00 Very Low Very Low Very Low
Demyelinating Disease 2 5.00 Very Low Very Low Very Low
Poisoning 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Therefore Omniscan® should not be used in these populations.Neonates and infants:Due to immature kidney function in neonates and infants up to 1 year of age, Omniscan® should only be used in these patients after careful consideration.Undesirable effects:Cases of NSF have been reported with Omniscan®.All other gadolinium — containing contrast agent s should add strong warnings about potential NSF with the following proposed SPC wording :Special warnings and precautions for use:There have been reports of NSF associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 ml/min per 1.73 m2).
NSF Binding (associated) of use in kidney associated with fibrosis
1) Confidence 0.03 Published 2007 Journal MAGMA Section Body Doc Link PMC2797854 Disease Relevance 0.59 Pain Relevance 0.26
For gadodiamide (Omniscan®) :Gadodiamide is contraindicated in patients with severe renal impairment (GFR < 30 ml/min per 1.73 m2), and those who have had or are undergoing liver transplantationSpecial warnings and precautions for use:Severe renal impairment and liver transplant patients:There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of gadodiamide and some other gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 ml/min per 1.73 m2) and those who have had or are undergoing liver transplantation.
NSF Binding (associated) of use in liver associated with nephrogenic fibrosing dermopathy and fibrosis
2) Confidence 0.02 Published 2007 Journal MAGMA Section Body Doc Link PMC2797854 Disease Relevance 0.39 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox